Health Advisory

Reinstatement of Haemophilus influenzae Type B (Hib) Booster Dose

July 1, 2009

This document will be updated as new information becomes available. The current version can always be viewed at http://www.dhss.mo.gov

The Missouri Department of Health & Senior Services (DHSS) is now using four types of documents to provide important information to medical and public health professionals, and to other interested persons:

- **Health Alerts** convey information of the highest level of importance which warrants immediate action or attention from Missouri health providers, emergency responders, public health agencies, and/or the public.
- **Health Advisories** provide important information for a specific incident or situation, including that impacting neighboring states; may not require immediate action.
- **Health Guidelines** contain comprehensive information pertaining to a particular disease or condition, and include recommendations, guidelines, etc. endorsed by DHSS.
- **Health Updates** provide new or updated information on an incident or situation; can also provide information to update a previously sent Health Alert, Health Advisory, or Health Guidance; unlikely to require immediate action.

Office of the Director
912 Wildwood
P.O. Box 570
Jefferson City, MO 65102
Telephone: (800) 392-0272
Fax: (573) 751-6041
Web site: http://www.dhss.mo.gov

FROM:  MARGARET T. DONNELLY
DIRECTOR

SUBJECT:  Reinstatement of Haemophilus influenzae Type B (Hib) Booster Dose

Effective immediately, the Centers for Disease Control and Prevention (CDC), in consultation with the Advisory Committee on Immunization Practices (ACIP), American Academy of Family Physicians (AAFP), and American Academy of Pediatrics (AAP), is recommending reinstatement of the booster dose of *Haemophilus influenzae* Type B (Hib) vaccine for children 12 to 15 months who have completed the primary series.

Production of Merck Hib vaccine products is still suspended. However, two other Hib containing vaccines, ActHIB and Pentacel, manufactured by Sanofi-Pasteur are available for use. Sufficient vaccine will be available to administer the primary series at 2, 4, and 6 months and a booster dose on time. Older children for whom the booster dose was deferred should receive their Hib booster dose at the next routinely scheduled visit or medical encounter. Although supply is sufficient to reinstate the booster dose and begin catch-up vaccination, supply is not sufficient to support a mass notification process to contact all children with deferred Hib booster doses. When additional Hib-containing vaccine becomes available to support active recall, CDC and the Vaccines for Children (VFC) Program will communicate this information to providers.

Providers with questions about their privately purchased supplies of monovalent Hib Vaccine (ActHIB) or DTaP-IPV/Hib (Pentacel) should contact Sanofi Pasteur’s customer service department (800-822-2463). Providers with questions regarding VFC vaccine orders should contact their VFC Program Liaison (800-219-3224). VFC providers should only place orders for a 4-6 week supply of vaccine, due to the fact that the VFC Program will continue to receive a monthly allotment of Hib-containing vaccine from CDC.

Providers should order ActHIB vaccine for children who have already received 4 doses of DTaP. We do not encourage providers to give Pentacel unless a child needs all components of the combination vaccine. However, a mismatch might exist between patient vaccination needs and the available stock of different vaccine formulations (combination products versus single-antigen vaccines). If DTAP-IPV/Hib (Pentacel) is the ONLY Hib-containing vaccine available, this combination product can be used to complete the series of Hib vaccination, even if the child already has received all the necessary doses of DTaP and IPV.

For your information, a recent Morbidity and Mortality Weekly Report (MMWR) article entitled "Updated Recommendations for Use of *Haemophilus influenzae* Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months" can be accessed at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5824a5.htm?s_cid=mm5824a15e.

Additional information for providers and patients is expected to be available from CDC by mid-July at http://www.cdc.gov/vaccines/vac-gen/shortages/default.htm.

Questions should be directed to the Missouri Department of Health and Senior Services’ (DHSS’) Bureau of Immunization Assessment and Assurance at (573) 751-6124 or (800) 219-3224.
IMPORTANT MESSAGE FROM CDC
PLEASE BE SURE TO SHARE THIS INFORMATION WITH THE LEAD PHYSICIAN
AND/OR CLINIC MANAGER IN YOUR FACILITY.

Dear Provider:

We want to let you know that beginning July 1, 2009, CDC reinstated the Hib booster dose for children 12 through 15 months. That is, children who are aged 12 through 15 months should receive the booster dose on time. The temporary recommendation to defer the Hib booster dose in healthy children, which began December 2007 because of a shortage of Hib vaccine, is no longer in effect. Sanofipasteur has increased the number of Hib vaccine doses available and providers should now be able to order some additional doses of Hib vaccine each month. However, the additional vaccine being made available is not sufficient to support an active recall of all children for whom the booster dose has been deferred. Rather, older children for whom the booster dose was previously deferred should receive the dose at the next routinely scheduled visit or medical encounter.

Please review these important points:

- As of July 1, 2009, infants should receive their primary Hib vaccine series at ages 2, 4, and 6 months, and a Hib booster dose on time at 12 through 15 months of age
- Older children for whom a Hib booster dose was deferred should receive their Hib booster dose at the next routinely scheduled visit or medical encounter
- Mass recall of children who require a Hib booster dose is not recommended at this time
  o We do not recommend using manual or automated recall mechanisms to actively contact patients.

For more detailed information on routine and catchup schedules for delivering Hib vaccines please see http://www.cdc.gov/vaccines/recs/schedules/default.htm#child.

If you have any questions, please contact CDC at 1-800-232-4636/1-800-CDC-INF0 or by email at www.cdc.gov/vaccines/about/contact/nipinfo_contact_form.htm.